<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837941</url>
  </required_header>
  <id_info>
    <org_study_id>0000-115</org_study_id>
    <secondary_id>2009_515</secondary_id>
    <nct_id>NCT00837941</nct_id>
  </id_info>
  <brief_title>A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)</brief_title>
  <official_title>Qualification of Single Dose Administration of Analgesic Therapy in the Treatment of Chronic Neuropathic Pain in Patients With Painful Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if analgesic efficacy can be detected with single
      dose administration in patients with chronic neuropathic pain due to painful diabetic
      neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>analgesic efficacy measured by patients self reported pain level after single dose administration</measure>
    <time_frame>5-11 hours after single dose is administered</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The onset of analgesic efficacy following single dose of pregabalin and duloxetine hydrochloride versus placebo</measure>
    <time_frame>24 hours after single dose is administered</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequence 1 - Pregabalin, Duloxetine hydrochloride, Diphenhydramine hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequence 2 - Duloxetine hydrochloride, Pregabalin, Diphenhydramine hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequence 3 - Diphenhydramine hydrochloride, Duloxetine hydrochloride, Pregabalin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequence 4 - Pregabalin, Diphenhydramine hydrochloride, Duloxetine hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequence 5 - Duloxetine hydrochloride, Diphenhydramine hydrochloride, Pregabalin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequence 6 - Diphenhydramine hydrochloride, Pregabalin, Duloxetine hydrochloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: A: Pregabalin</intervention_name>
    <description>1 Pregabalin 300 mg capsule</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: B: Duloxetine</intervention_name>
    <description>1 Duloxetine hydrochloride 60 mg capsule</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: C: Diphenhydramine hydrochloride</intervention_name>
    <description>1 Diphenhydramine hydrochloride 25mg capsule</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been treated for type 1 or 2 diabetes mellitus with glycosylated
             hemoglobin

          -  Patient has pain in both feet that occurred after onset of diabetes

          -  Patient agrees to maintain a consistent activity level throughout the study

          -  Patient is not on chronic pain therapy, or is on a stable dose of one pain therapy

          -  Female patients of reproductive potential must agree to use two acceptable methods of
             birth control through out the study

          -  Patients taking a pain medication must be on a stable dose at least 1 month prior to
             participating in study

        Exclusion Criteria:

          -  Patient has a history of congestive heart failure

          -  Patient has/had a seizure disorder

          -  Patient has tried and failed 3 or more drugs to treat neuropathic pain

          -  Patient is currently taking pregabalin or duloxetine hydrochloride

          -  Patient has had a malignancy within the past 2 years (excluding basal cell carcinoma)

          -  Patient has history of hepatitis B or C or HIV infection

          -  Patient has skin-condition that may decrease sensitivity in area of neuropathic pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <last_update_submitted>July 24, 2015</last_update_submitted>
  <last_update_submitted_qc>July 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

